Advanced search
1 file | 765.06 KB
Author
Organization
Abstract
Background : Self-harm (SH; intentional self-poisoning or self-injury) is common, often repeated, and strongly associated with suicide. This is an update of a broader Cochrane review on psychosocial and pharmacological treatments for deliberate SH, first published in 1998 and previously updated in 1999. We have now divided the review into three separate reviews. This review is focused on pharmacological interventions in adults who self harm. Objectives : To identify all randomised controlled trials of pharmacological agents or natural products for SH in adults, and to conduct meta-analyses (where possible) to compare the effects of specific treatments with comparison types of treatment (e.g., placebo/alternative pharmacological treatment) for SH patients. Search methods : For this update the Cochrane Depression, Anxiety and Neurosis Review Group (CCDAN) Trials Search Co-ordinator searched the CCDAN Specialised Register (September 2014). Additional searches of MEDLINE, EMBASE, PsycINFO, and CENTRAL were conducted to October 2013. Selection criteria : We included randomised controlled trials comparing pharmacological treatments or natural products with placebo/alternative pharmacological treatment in individuals with a recent (within six months) episode of SH resulting in presentation to clinical services. Data collection and analysis : We independently selected trials, extracted data, and appraised trial quality. For binary outcomes, we calculated odds ratios (ORs) and their 95% confidence intervals (CIs). For continuous outcomes we calculated the mean difference (MD) and 95% CI. Meta-analysis was only possible for one intervention (i.e. newer generation antidepressants) on repetition of SH at last follow-up. For this analysis, we pooled data using a random-effects model. The overall quality of evidence for the primary outcome was appraised for each intervention using the GRADE approach. Main results : We included seven trials with a total of 546 patients. The largest trial included 167 participants. We found no significant treatment effect on repetition of SH for newer generation antidepressants (n = 243; k = 3; OR 0.76, 95% CI 0.42 to 1.36; GRADE: low quality of evidence), low-dose fluphenazine (n = 53; k = 1; OR 1.51, 95% CI 0.50 to 4.58; GRADE: very low quality of evidence), mood stabilisers (n = 167; k = 1; OR 0.99, 95% CI 0.33 to 2.95; GRADE: low quality of evidence), or natural products (n = 49; k = 1; OR 1.33, 95% CI 0.38 to 4.62; GRADE: low quality of evidence). A significant reduction in SH repetition was found in a single trial of the antipsychotic flupenthixol (n = 30; k = 1; OR 0.09, 95% CI 0.02 to 0.50), although the quality of evidence for this trial, according to the GRADE criteria, was very low. No data on adverse effects, other than the planned outcomes relating to suicidal behaviour, were reported. Authors' conclusions : Given the low or very low quality of the available evidence, and the small number of trials identified, it is not possible to make firm conclusions regarding pharmacological interventions in SH patients. More and larger trials of pharmacotherapy are required. In view of an indication of positive benefit for flupenthixol in an early small trial of low quality, these might include evaluation of newer atypical antipsychotics. Further work should include evaluation of adverse effects of pharmacological agents. Other research could include evaluation of combined pharmacotherapy and psychological treatment.
Keywords
BORDERLINE PERSONALITY-DISORDER, RANDOMIZED CONTROLLED-TRIALS, METAANALYSIS COMBINING PARALLEL, TREATMENT-RESISTANT DEPRESSION, TERM, LITHIUM TREATMENT, OVER CLINICAL-TRIALS, SUICIDE RISK, BIPOLAR DISORDER, MOOD DISORDERS, DOUBLE-BLIND

Downloads

  • witt-pharmacologicalinter-2015.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 765.06 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Hawton, Keith, Katrina Witt, Tatiana Salisbury, Ella Arensman, David Gunnell, Philip Hazell, Ellen Townsend, and Cornelis Van Heeringen. 2015. “Pharmacological Interventions for Self-harm in Adults.” Cochrane Database of Systematic Reviews (7).
APA
Hawton, K., Witt, K., Salisbury, T., Arensman, E., Gunnell, D., Hazell, P., Townsend, E., et al. (2015). Pharmacological interventions for self-harm in adults. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (7).
Vancouver
1.
Hawton K, Witt K, Salisbury T, Arensman E, Gunnell D, Hazell P, et al. Pharmacological interventions for self-harm in adults. COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2015;(7).
MLA
Hawton, Keith, Katrina Witt, Tatiana Salisbury, et al. “Pharmacological Interventions for Self-harm in Adults.” COCHRANE DATABASE OF SYSTEMATIC REVIEWS 7 (2015): n. pag. Print.
@article{8573471,
  abstract     = {Background : Self-harm (SH; intentional self-poisoning or self-injury) is common, often repeated, and strongly associated with suicide. This is an update of a broader Cochrane review on psychosocial and pharmacological treatments for deliberate SH, first published in 1998 and previously updated in 1999. We have now divided the review into three separate reviews. This review is focused on pharmacological interventions in adults who self harm. 
Objectives : To identify all randomised controlled trials of pharmacological agents or natural products for SH in adults, and to conduct meta-analyses (where possible) to compare the effects of specific treatments with comparison types of treatment (e.g., placebo/alternative pharmacological treatment) for SH patients. 
Search methods : For this update the Cochrane Depression, Anxiety and Neurosis Review Group (CCDAN) Trials Search Co-ordinator searched the CCDAN Specialised Register (September 2014). Additional searches of MEDLINE, EMBASE, PsycINFO, and CENTRAL were conducted to October 2013. 
Selection criteria : We included randomised controlled trials comparing pharmacological treatments or natural products with placebo/alternative pharmacological treatment in individuals with a recent (within six months) episode of SH resulting in presentation to clinical services. 
Data collection and analysis : We independently selected trials, extracted data, and appraised trial quality. For binary outcomes, we calculated odds ratios (ORs) and their 95\% confidence intervals (CIs). For continuous outcomes we calculated the mean difference (MD) and 95\% CI. Meta-analysis was only possible for one intervention (i.e. newer generation antidepressants) on repetition of SH at last follow-up. For this analysis, we pooled data using a random-effects model. The overall quality of evidence for the primary outcome was appraised for each intervention using the GRADE approach. 
Main results : We included seven trials with a total of 546 patients. The largest trial included 167 participants. We found no significant treatment effect on repetition of SH for newer generation antidepressants (n = 243; k = 3; OR 0.76, 95\% CI 0.42 to 1.36; GRADE: low quality of evidence), low-dose fluphenazine (n = 53; k = 1; OR 1.51, 95\% CI 0.50 to 4.58; GRADE: very low quality of evidence), mood stabilisers (n = 167; k = 1; OR 0.99, 95\% CI 0.33 to 2.95; GRADE: low quality of evidence), or natural products (n = 49; k = 1; OR 1.33, 95\% CI 0.38 to 4.62; GRADE: low quality of evidence). A significant reduction in SH repetition was found in a single trial of the antipsychotic flupenthixol (n = 30; k = 1; OR 0.09, 95\% CI 0.02 to 0.50), although the quality of evidence for this trial, according to the GRADE criteria, was very low. No data on adverse effects, other than the planned outcomes relating to suicidal behaviour, were reported. 
Authors' conclusions : Given the low or very low quality of the available evidence, and the small number of trials identified, it is not possible to make firm conclusions regarding pharmacological interventions in SH patients. More and larger trials of pharmacotherapy are required. In view of an indication of positive benefit for flupenthixol in an early small trial of low quality, these might include evaluation of newer atypical antipsychotics. Further work should include evaluation of adverse effects of pharmacological agents. Other research could include evaluation of combined pharmacotherapy and psychological treatment.},
  articleno    = {CD011777},
  author       = {Hawton, Keith and Witt, Katrina and Salisbury, Tatiana and Arensman, Ella and Gunnell, David and Hazell, Philip and Townsend, Ellen and Van Heeringen, Cornelis},
  issn         = {1469-493X},
  journal      = {COCHRANE DATABASE OF SYSTEMATIC REVIEWS},
  language     = {eng},
  number       = {7},
  pages        = {64},
  title        = {Pharmacological interventions for self-harm in adults},
  url          = {http://dx.doi.org/10.1002/14651858.CD011777},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: